Greenfire Bio

Greenfire Bio is an oncology-focused, clinical-stage biopharmaceutical company based in Frisco, Texas, dedicated to accelerating the development of innovative cancer therapies. We specialize in identifying and advancing promising early-stage assets through clinical proof-of-concept and beyond, leveraging a robust network of experienced pharmaceutical experts and strategic partnerships. Since 2020, Greenfire Bio has successfully acquired and developed a first-in-class small molecule SIK2/3 inhibitor (GRN300) currently in Phase 1 clinical trials, and has invested in Pacylex’s NMT1/NMT2 inhibitor (PCLX001), which is in Phase 2 testing for hematological malignancies and solid tumors. Through our subsidiaries, Green3Bio and MGFB Bio, we are committed to translating groundbreaking research into impactful medical products, ultimately providing patients with access to life-saving treatments. We focus on addressing serious unmet medical needs and delivering superior returns to our investors by strategically monetizing our pipeline through licensing, sale, or IPO.